Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>In this note, we will take a look at the Asia Pacific IPO pipeline for 2025, starting with Hong Kong.</li>
<li>This list has been compiled on a best effort basis from tracking the company filings and through various other sources.</li>
<li>The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.</li>
</ul>


In this note, we will take a look at the Asia Pacific IPO pipeline for 2025, starting with Hong Kong.
This list has been compiled on a best effort basis from tracking the company filings and through various other sources.
The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.


Aequitas 2025 Asia IPO Pipeline - Hong Kong

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/111-inc" target="_blank" data-smartkarma-citation="entities:27412:1" rel="noopener">111 Inc (YI US)</a>, China's largest virtual pharmacy network, <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&amp;ref=317622517&amp;type=PDF&amp;symbol=YI&amp;cdn=576c7a62e80e529bffa675d5bed28708&amp;companyName=111+Inc.&amp;formType=SC+13D%2FA&amp;dateFiled=2023-07-17" target="_blank" rel="noopener">amended an SC 13D filing</a> on 13 July, which belatedly updated the consortium’s privatisation offer of US$3.66 per ADS. </li>
<li>The consortium has been revamped such that the lead investors (Dr Gang Yu, Dr Junling Liu and Shanghai Guosheng Capital Management) are joined with 13 additional investors.</li>
<li>The development facilitates the signing of a definite agreement. The consortium represents 95.27% of the voting power, which ensures a successful vote. At last close, the gross spread is 9.6%.</li>
</ul>



111 Inc (YI US), China's largest virtual pharmacy network, amended an SC 13D filing on 13 July, which belatedly updated the consortium’s privatisation offer of US$3.66 per ADS. 
The consortium has been revamped such that the lead investors (Dr Gang Yu, Dr Junling Liu and Shanghai Guosheng Capital Management) are joined with 13 additional investors.
The development facilitates the signing of a definite agreement. The consortium represents 95.27% of the voting power, which ensures a successful vote. At last close, the gross spread is 9.6%.


111 (YI US): The Privatisation Offer Gets a Reboot

APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

Jiangsu Fangzhou Chemical / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/fangzhou-group" target="_blank" data-smartkarma-citation="entities:36560:1" rel="noopener">Fangzhou Group (FANGZHOU HK)</a> is looking to raise about US$300m in its upcoming Hong Kong IPO.</li>
<li>Fangzhou (FZ) is an online chronic disease management (CDM) service provider in China.</li>
<li>In this note, we will talk about the not-so-positive aspects of the deal.</li>
</ul>



Fangzhou Group (FANGZHOU HK) is looking to raise about US$300m in its upcoming Hong Kong IPO.
Fangzhou (FZ) is an online chronic disease management (CDM) service provider in China.
In this note, we will talk about the not-so-positive aspects of the deal.


Fangzhou Pre-IPO - The Negatives - Hard to Shake off Loss-Making Tendencies

<ul>
<li>
<a href="https://www.smartkarma.com/entities/fangzhou-group" target="_blank" data-smartkarma-citation="entities:36560:1" rel="noopener">Fangzhou Group (FANGZHOU HK)</a> is looking to raise about US$300m in its upcoming Hong Kong IPO.</li>
<li>Fangzhou (FZ) is an online chronic disease management (CDM) service provider in China.</li>
<li>In this note, we will talk about the positive aspects of the deal.</li>
</ul>



Fangzhou Group (FANGZHOU HK) is looking to raise about US$300m in its upcoming Hong Kong IPO.
Fangzhou (FZ) is an online chronic disease management (CDM) service provider in China.
In this note, we will talk about the positive aspects of the deal.


Fangzhou Pre-IPO - The Positives - Regulatory Changes and COVID Spurred Growth

<ul>
<li>In this note, we will take a look at the Asia Pacific IPO pipeline for 2023, starting with Hong Kong. </li>
<li>This list has been compiled on a best effort basis from tracking the company filings and through various other sources.</li>
<li>The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.</li>
</ul>


In this note, we will take a look at the Asia Pacific IPO pipeline for 2023, starting with Hong Kong. 
This list has been compiled on a best effort basis from tracking the company filings and through various other sources.
The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.


Aequitas 2023 Asia IPO Pipeline - Hong Kong

China

Wedoctor Group operates health care software businesses. The Company provides registration, medical advice, and other services. Wedoctor Group conducts business in China. 

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

WeDoctor Holdings (1737089D HK)

Aequitas 2025 Asia IPO Pipeline - Hong Kong

In this note, we will take a look at the Asia Pacific IPO pipeline for 2025, starting with Hong Kong where the number of filings have been...

Sumeet Singh

111 (YI US): The Privatisation Offer Gets a Reboot

The revamped consortium facilitates the signing of a definite agreement. The consortium represents 95.27% of the voting power, which ensures a...

Arun George

Fangzhou Pre-IPO - The Negatives - Hard to Shake off Loss-Making Tendencies

Fangzhou Group (FANGZHOU HK) is looking to raise about US$300m in its upcoming Hong Kong IPO. In this note, we will talk about the not-so-positive...

Clarence Chu

Fangzhou Pre-IPO - The Positives - Regulatory Changes and COVID Spurred Growth

Fangzhou Group (FANGZHOU HK) is looking to raise about US$300m in its upcoming Hong Kong IPO. In this note, we will talk about the positive aspects...

Clarence Chu

Aequitas 2023 Asia IPO Pipeline - Hong Kong

In this note, we will take a look at the Asia Pacific IPO pipeline for 2023, starting with Hong Kong. The deals you see are only a part of the...

Sumeet Singh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)